Long-term meloxicam monitoring in dogs centers on periodic renal and hepatic biochemistry, with risk minimization built around hydration status, drug interactions, and gastrointestinal protection.

Baseline bloodwork before initiating therapy and periodic rechecks during long-term use are the standard of care. The monitoring interval should be individualized, with more frequent assessment in patients with pre-existing renal, hepatic, or cardiovascular disease. Dogs at greatest risk for renal toxicity are those that are dehydrated, on concurrent diuretic therapy, or those with existing renal, cardiovascular, or hepatic dysfunction. FDA DailyMed An…+2

Renal parameters to track include blood urea nitrogen (BUN), creatinine, and urinalysis. In the 3-day injectable safety study, BUN increases occurred at the 1× recommended dose, and two dogs developed acute renal failure at 5× the recommended dose, with renal histopathology showing dilated tubules, interstitial inflammation, and papillary tip necrosis at doses as low as 1×. FDA DailyMed An… In post-approval surveillance, azotemia, elevated creatinine, and renal failure have all been reported at clinical doses. FDA DailyMed An… In cases of impaired renal function, dose reduction is recommended. Journal of the…

Hepatic monitoring should include alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Elevated liver enzymes have been reported in post-approval adverse event surveillance. FDA DailyMed An… In the injectable safety study, ALP was significantly increased at 1× and 5× doses. FDA DailyMed An… Hepatotoxicity is considered rare and largely idiosyncratic. WSAVA Global Gu…

Gastrointestinal signs — vomiting, soft stools, diarrhea, and inappetence — are the most commonly reported adverse reactions in clinical use. In the 224-dog field study, gastrointestinal abnormalities were the leading adverse event category. FDA DailyMed An… Post-approval reporting has documented vomiting, diarrhea, melena, and gastrointestinal ulceration. FDA DailyMed An… In the 6-month oral safety study, gastrointestinal distress occurred across all dose groups including controls, and endoscopic gastric mucosal reddening was observed at the recommended dose in 3 dogs. FDA DailyMed An…

To minimize renal risk, ensure the patient is well hydrated before and during therapy, and avoid concurrent nephrotoxic drugs. Concurrent administration of potentially nephrotoxic drugs requires careful consideration. FDA DailyMed An…+2 Diuretic co-administration is a specific risk factor for renal toxicity. FDA DailyMed An…+1 Dogs with cardiovascular disease — such as those with significant heart murmurs — carry compounded renal risk, as prostaglandin inhibition can compromise renal perfusion in low-output states. FDA DailyMed An…+2

To minimize gastrointestinal risk, avoid concurrent use of other NSAIDs or corticosteroids. Concomitant use of corticosteroids or a second NSAID is contraindicated due to additive ulcerogenic risk. FDA DailyMed An… If additional analgesia is needed beyond the total daily meloxicam dose, a non-NSAID, non-corticosteroid analgesic class should be used instead. FDA DailyMed An… An appropriate washout period is required when switching from corticosteroids or from one NSAID to another. FDA DailyMed An…

Meloxicam is contraindicated in dogs with bleeding disorders, and safety has not been established in dogs under 6 months of age, breeding dogs, or pregnant or lactating bitches. FDA DailyMed An…+2 Dogs that have experienced an adverse reaction to one NSAID are at increased risk of adverse reactions to another. FDA DailyMed An…+2

Long-term NSAID use in dogs does not show increased organ-based toxicity with longer treatment duration, and studies demonstrate a positive trend toward increased efficacy over time. AAHA Clinical G… The true incidence of clinically significant renal, hepatic, and gastrointestinal toxicity at therapeutic doses is considered low. AAHA Clinical G…

Would you like guidance on selecting an alternative analgesic when meloxicam needs to be discontinued due to renal or gastrointestinal concerns?

1.
MELOXIDYL (meloxicam). FDA Drug Label.
Food and Drug Administration.Updated: 2025-07-30.
New
2.
OstiLox (meloxicam). FDA Drug Label.
Food and Drug Administration.Updated: 2025-07-29.
New
3.
Metacam (meloxicam). FDA Drug Label.
Food and Drug Administration.Updated: 2025-01-23.
4.
Meloxicam may induce nephrotoxicity in California sea lions (Zalophus californianus) with chronic domoic acid toxicosis.
Journal of the American Veterinary Medical Association.2025.Peters M, Duignan P, E Martinez M, et al.
Top Journal
New
5.
Pain Guidelines - WSAVA
WSAVA Global Guidelines.
Top Journal

Related Questions

How do I manage a dog with suspected NSAID toxicity including GI and renal complication monitoring?How do I diagnose and manage Shar-Pei fever and the associated risk of renal amyloidosis?How should I treat a dog envenomated by a pit viper including antivenom indications and monitoring?What is the treatment protocol for a cat that ingested any part of a true lily including emesis and renal monitoring?What is the technique and indications for autotransfusion in a dog with hemoabdomen?how do I approach the workup and management of a dog presenting for owner-directed aggression?How do I grade a cardiac murmur in a dog and what workup is warranted at each grade?What is the recommended diagnostic approach for acute diarrhea in an otherwise stable dog?
What monitoring is required for a dog on long-term… | VetChamp